Research programme: Huntington's disease therapeutics - Provid Pharmaceuticals/Duke University
Latest Information Update: 20 Nov 2007
At a glance
- Originator Duke University Medical Center; Provid Pharmaceuticals
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 19 Aug 2003 Preclinical trials in Huntington's disease in USA (unspecified route)